Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
NCT03220022
Recruiting
This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human immunodeficiency virus (HIV)-positive stage II-IV diffuse large B-cell lymphomas. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: UC San Diego Moores Cancer Center, La Jolla, California +20 locations
Conditions: AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Register for Updates
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
NCT05111574
Recruiting
This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. T... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Sutter Auburn Faith Hospital, Auburn, California +141 locations
Conditions: Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Vaginal Melanoma, Vulvar Melanoma, Head and Neck Mucosal Melanoma, Nasopharyngeal Mucosal Melanoma, Urinary System Mucosal Melanoma
Register for Updates
HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)
NCT05677360
Recruiting
This intervention study will use parent-, provider-, and health center-level strategies to promote HPV vaccination among 11-17 year olds receiving care in 8 community health centers in Florida, will explore factors related to the intervention effect, and will explore implementation outcomes of the intervention.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Human Papilloma Virus (HPV) Vaccine
Register for Updates
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910
Recruiting
The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active Crohn's Disease (CD) after 12 weeks of treatment. Other aims are to learn how safe and effective DTT is compared to monotherapy for these participants. All participants will receive DTT (either vedolizumab and upad... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2025
Locations: UCSD Medical Center, La Jolla, California +137 locations
Conditions: Crohn's Disease
Register for Updates
The PROACTIVE Study for Black Elders
NCT06512727
Recruiting
Chronic musculoskeletal pain (CMP), while a leading cause of physical disablement, is a neglected national health disparity issue in Black communities. The purpose of this study is to test a novel culturally congruent pain self-management intervention. A total of 120 persons aged 50-92, self-identifying as Black or African American having CMP will be invited to participate in this study. The primary outcome measured throughout this 3-year study is movement-evoked pain (MEP).
Gender:
ALL
Ages:
Between 50 years and 92 years
Trial Updated:
05/08/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Musculoskeletal Pain, Chronic Pain, Osteoarthritis, Pain, Chronic, Movement Evoked Pain
Register for Updates
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
NCT06664814
Recruiting
Background: Focal segmental glomerulosclerosis (FSGS) is a disease that causes scarring in parts of the kidneys that filter waste. This can lead to protein loss in the urine, which can worsen kidney function. The kidneys may fail over time, and dialysis or a kidney transplant may be needed. Other treatments for this disease do not always work and often have adverse effects. Better treatments for FSGS are needed. Objective: To test a study drug (ManNAc) in people with FSGS. Eligibility: Peop... Read More
Gender:
ALL
Ages:
Between 18 years and 115 years
Trial Updated:
05/08/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
Samples From Human Subjects to Facilitate Basic, Translational and Clinical Research
NCT03253705
Recruiting
Background: This study is designed to provide samples to help us study the genes your blood cells are making as well as the proteins, sugars, fats, vitamins and other metabolites found in your blood or urine. Blood samples may also be collected to make special cells. These are called induced pluripotent stem cells or iPSCs. Pluripotent stem cells are cells that can be converted into any type of cell. Researchers want to study in the lab iPSCs that are derived from blood samples. Objective: To... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/08/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Endothelial Dysfunction, Inflammation in Cardiopulmonary and Vascular Disease States, Healthy Volunteers
Register for Updates
Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease
NCT05170412
Recruiting
Background: Sickle Cell Disease (SCD) causes blood cells form a crescent shape. It is caused by a genetic mutation in the hemoglobin gene. People with SCD are at increased risk for illnesses like stroke, chronic pain, and heart problems, as well as decreased overall health and well-being. Researchers want to learn more about how nutrition and diet can help relieve or reduce the symptoms of SCD. Objective: To understand how diet, dietary patterns and behaviors, nutrition, and other related fac... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/08/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Disease
Register for Updates
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
NCT05711940
Recruiting
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Clinical Innovations, Inc., Bellflower, California +93 locations
Conditions: Treatment Resistant Depression
Register for Updates
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
NCT06238921
Recruiting
This is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases, compared to treatment with Sacituzumab Govitecan alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer, Triple Negative Breast Cancer
Register for Updates
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
NCT06512883
Recruiting
The main purpose of study is to assess the safety, tolerability, and pharmacokinetic (PK) of benralizumab.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
05/08/2025
Locations: Research Site, Aurora, Colorado +5 locations
Conditions: Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Register for Updates
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
NCT06697197
Recruiting
The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Local Institution - 0005, Irvine, California +20 locations
Conditions: Advanced Solid Tumors
Register for Updates